Earlier this year, a study published in Nature Medicine captured global attention with a striking claim: administering immunotherapy infusions in the morning rather than the afternoon doubled progression-free and overall survival times for advanced lung cancer patients. The findings, derived from a clinical trial conducted at Hunan Cancer Hospital in China, suggested a simple, cost-free scheduling change could yield benefits typically associated with novel blockbuster drugs.
The report prompted immediate interest from oncologists and patients alike, with cancer centers fielding numerous requests to shift infusion schedules to morning hours. However, on Wednesday, Nature Medicine retracted the paper, citing a constellation of serious irregularities that undermined confidence in the data.
“It was too good to be true,” said Dr. Toni Choueiri of the Dana-Farber Cancer Institute, who participated in the post-publication review that precipitated the retraction.
The journal’s retraction notice detailed multiple critical flaws: study records intended to be locked prior to enrollment were modified after the trial began; discrepancies existed between the original Chinese protocol and the English translation; zero patient dropouts due to adverse events were recorded over the first year — a statistical anomaly in oncology research; and unusual patterns emerged in the timing of follow-up imaging scans.
“Due to the amount and nature of the problems identified, the editors no longer have confidence in the integrity of the results,” the journal stated.
The 28-author study, primarily led by researchers in China with European collaborators and government funding, enrolled 210 patients randomized to receive Merck’s Keytruda or the China-approved drug Tyvyt either before or after 3 p.m. It reported median progression-free survival of 11 months for the morning group versus six months for the afternoon cohort, with overall survival of 28 months versus 17 months, respectively.
Experts noted the biological implausibility of such dramatic effects from timing alone. Keytruda persists in the body for weeks, and the study offered no mechanistic rationale for a circadian-based benefit of this magnitude. A subsequent independent analysis of over 3,000 patients across eight trials, funded by Roche, found no significant association between infusion timing and outcomes.
Dr. Yongchang Zhang, the study’s senior author, acknowledged in a statement that “part of the study execution and manuscript preparation might not reach the standards for publication in a high-impact journal,” apologizing for the shortcomings without addressing the specific irregularities cited.
The episode arrives amid heightened scrutiny of China’s rapidly expanding biomedical research enterprise. While the nation has become a formidable force in drug development, concerns persist regarding variability in research rigor. Observers noted that confounding factors — such as healthier patients preferentially selecting morning appointments or travel burdens forcing sicker, rural patients into afternoon slots — could explain observational associations between timing and outcomes in other datasets.
Dr. Anil Makam of the University of California, San Francisco, had observed shortly after publication that if the results were genuine, failing to reschedule infusions would constitute malpractice. The retraction now serves as a cautionary case study in the importance of post-publication peer review and the risks of implementing practice-changing interventions before independent replication.
